<DOC>
	<DOC>NCT01867957</DOC>
	<brief_summary>1. BACKGROUND The newly developed anthrax vaccine GC1109 has been proven safe and effective in preclinical studies. 2. OBJECTIVE - To evaluate the immunogenicity and safety of the anthrax vaccine GC1109 in healthy male volunteers. 3. STUDY DESIGN - single-blinded - randomized - placebo controlled - phase 1 study</brief_summary>
	<brief_title>Efficacy and Safety of Anthrax Vaccine, GC1109</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Healthy male subjects between 18 and 45 years of age at the time of screening visit 2. 18.5kg/m2 â‰¤BMI &lt; 30kg/m2 at the time of screening visit 3. Subjects without congenital or chronic disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>anthrax</keyword>
	<keyword>vaccine</keyword>
	<keyword>bioterrorism</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>